Neil Bodie

Company: Paradigm Immunotherapeutics Inc.

Job title: Chief Executive Officer

Seminars:

Inhibition of IgG Multimer & Hexamer Formation Using an Fc Silent Extended Half-life Fc Fusion Protein 12:00 pm

• Design and structure of Fc silent artificial rheumatoid factor • Review of IgG hexamer formation after immune complex formation • Review of FcRn structure and function and how that can be used to extend the half-life of Fc proteins and monoclonal antibodies. Very brief discussion on FcRn being a cofactor of CD32aRead more

day: Conference Day Two

Translating Fc-Mediated Therapeutics to Clinic Across More Diverse Disease Landscapes for More Efficacious Treatment 1:30 pm

Expanding the therapeutic application of Fc-mediated therapies to unlock their potential beyond standard indications to open new avenues for treating complex diseases like cancer, autoimmune disorders, and arthritis. This workshop will focus on: Analysing the comparative immunological landscape in cancer, autoimmune diseases, and arthritis to identify disease-specific pathophysiological mechanisms to enable the precise selection of…Read more

day: Pre-Conference Day